RecruitingNCT06481826
Glofitamab in Chinese Patients With R/R DLBCL
A Study to Evaluate Glofitamab as Single Agent in Chinese Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Sponsor
Peking Union Medical College Hospital
Enrollment
20 participants
Start Date
Jan 1, 2024
Study Type
OBSERVATIONAL
Conditions
Summary
This study will evaluate the safety and efficacy of glofitamab as a single agent in Chinese patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) who have failed two or more lines of systemic therapy.
Eligibility
Min Age: 18 YearsMax Age: 80 Years
Inclusion Criteria3
- Histologically-confirmed DLBCL
- Participants must have relapsed or failed to respond to at least two lines of prior systemic therapy
- Participants must have measurable disease
Exclusion Criteria5
- Pregnancy or breastfeeding
- Patient with known active infection, or reactivation of a latent infection
- Patient with active autoimmune disease or immune deficiency
- severe organ failure：LVEF\<40%；DLCO\<40%；eGFR\<30ml/min；Bilirubin≥3ULN
- Patients who are dependent on the sponsor, the investigator or the trial site
Interventions
DRUGGlofitamab
Glofitamab given in standard dosage
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06481826
Related Trials
CAR-T Followed by Bispecific Antibodies
NCT048897162 locations
Dose Escalation and Dose Expansion Study of MDX2003 in Patients With Different Types of Lymphoma
NCT072499051 location
P-CD19CD20-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With B Cell Malignancies
NCT0601476217 locations
This is a Phase 1 Study to Evaluate the Safety of LTZ-301 in Patients With Non-Hodgkin Lymphoma
NCT071219465 locations
Zanubrutinib in Patients With DLBCL and MYD88 or NOTCH1 Mutation or CD5+
NCT068464631 location